Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 20/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.59 |
| ▸ | PDE1A | P54750 | 10/20 | 0.59 |
| ▸ | PDE1B | Q01064 | 10/20 | 0.59 |
| ▸ | PDE1C | Q14123 | 10/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.56 |
| ▸ | PDE5A | O76074 | 4/20 | 0.55 |
| ▸ | PDE7B | Q9NP56 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8108241 | 0.99 | PDE7A (0.58) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL29408510 | 0.99 | PDE7A (0.58) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL299743 | 0.91 | PDE7A (0.62) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL2681013 | 0.90 | PDE7A (0.60) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL298932 | 0.88 | PDE7A (0.52) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL30837954 | 0.88 | PDE7A (0.52) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL3020452 | 0.86 | PDE7A (0.55) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL3020050 | 0.86 | PDE7A (0.65) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL298757 | 0.86 | PDE7A (0.62) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL299352 | 0.86 | PDE7A (0.52) | PDE7APDE4DPDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216823-A1 | Spirocyclic Derivatives | PFIZER INC. | 2010-08-26 | — | — | US | claimed |
| EP-2160381-A2 | SPIROCYCLIC QUINAZOLINE DERIVATIVES AND THEIR USE AS PDE7 INHIBITORS | Pfizer Limited (GB) | 2010-03-10 | — | — | EP | claimed |
| WO-2008142550-A9 | SPIROCYCLIC QUINAZOLINE DERIVATIVES AND THEIR USE AS PDE7 INHIBITORS | PFIZER LIMITED (GB) | 2010-02-11 | — | — | WO | claimed |
| WO-2008142550-A2 | SPIROCYCLIC DERIVATIVES | PFIZER LIMITED (GB) | 2008-11-27 | — | — | WO | claimed |
| EP-4275752-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION | 2023-04-13 | — | — | US | disclosed |
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20190134055-A1 | Treatment of Addiction and Impulse-control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2019-05-09 | — | — | US | disclosed |
| EP-2846805-B1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORP (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180289632-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2018-10-11 | — | — | US | disclosed |
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2016-01-21 | — | — | US | disclosed |
| US-20100216823-A1 | Spirocyclic Derivatives | PFIZER INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216823-A1 | Spirocyclic Derivatives | PFIZER INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2160381-A2 | SPIROCYCLIC QUINAZOLINE DERIVATIVES AND THEIR USE AS PDE7 INHIBITORS | Pfizer Limited (GB) | 2010-03-10 | — | — | EP | disclosed |
| WO-2008142550-A9 | SPIROCYCLIC QUINAZOLINE DERIVATIVES AND THEIR USE AS PDE7 INHIBITORS | PFIZER LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
| WO-2008142550-A9 | SPIROCYCLIC QUINAZOLINE DERIVATIVES AND THEIR USE AS PDE7 INHIBITORS | PFIZER LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
| WO-2008142550-A2 | SPIROCYCLIC DERIVATIVES | PFIZER LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008142550-A2 | SPIROCYCLIC DERIVATIVES | PFIZER LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289632-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885PDE4D 7/4885PDE1A 21/4885 |
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885PDE4D 7/4885PDE1A 21/4885 |
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885PDE4D 7/4885PDE1A 21/4885 |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | PDE7B, PDE4C, PDE4A | PDE7A 10/4885PDE4D 7/4885PDE1A 21/4885 |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | PDE7A 3/4885PDE4D 16/4885PDE1A 14/4885 |
| US-20190134055-A1 | Treatment of Addiction and Impulse-control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885PDE4D 7/4885PDE1A 21/4885 |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | PDE7A 3/4885PDE4D 16/4885PDE1A 14/4885 |
| US-20100216823-A1 | Spirocyclic Derivatives | PDE7B, PDE6B, PDE7A | PDE7A 3/4885PDE4D 22/4885PDE1A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.